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Abstract
A bivariate mixture model utilizing information across two species was proposed to solve the fundamental problem of
identifying diﬀerentially expressed genes in microarray experiments. The model utility was illustrated using a dog and
human lymphoma data set prepared by a group of scientists in the College of Veterinary Medicine at North Carolina
State University. A small number of genes were identiﬁed as being diﬀerentially expressed in both species and the
human genes in this cluster serve as a good predictor for classifying diﬀuse large-B-cell lymphoma (DLBCL) patients
into two subgroups, the germinal center B-cell-like diﬀuse large B-cell lymphoma and the activated B-cell-like diﬀuse
large B-cell lymphoma. The number of human genes that were observed to be signiﬁcantly diﬀerentially expressed
(21) from the two-species analysis was very small compared to the number of human genes (190) identiﬁed with only
one-species analysis (human data). The genes may be clinically relevant/important, as this small set achieved low
misclassiﬁcation rates of DLBCL subtypes. Additionally, the two subgroups deﬁned by this cluster of human genes had
signiﬁcantly diﬀerent survival functions, indicating that the stratiﬁcation based on gene-expression proﬁling using the
proposed mixture model provided improved insight into the clinical diﬀerences between the two cancer subtypes.
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Introduction
Diﬀuse large-B-cell lymphoma (DLBCL), the most com-
mon type of non-Hodgkin lymphoma in adults, accounts
for 30% to 40% of newly diagnosed lymphomas and has an
annual incidence in America of more than 25,000 cases.
Combination chemotherapy has transformed DLBCL
from a fatal disease into one that is often curable, but
only approximately 50% of all patients are cured [1,2].
This suggests that DLBCL actually comprises several
subgroups that diﬀer in responsiveness to chemother-
apy. The attempts to deﬁne subgroups of DLBCL have
often failed due to diagnostic discrepancies. Clinically, the
International Prognostic Index (IPI) [3] has been devel-
oped for use in the design of future therapeutic trials in
patients with aggressive non-Hodgkin lymphoma and in
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the selection of appropriate therapeutic approaches for
individual patients. However, IPI has not been used suc-
cessfully to predict outcomes in DLBCLs so that patients
can be stratiﬁed correctly for therapeutic trials. This may
be attributed to the fact that the clinical factors of IPI (age,
tumor stage, serum lactate dehydrogenase concentration,
performance status, and number of extranodal disease
sites) neither provide molecular insight into the hetero-
geneity of DLBCL nor identify speciﬁc therapeutic targets
[4,5].
Recent developments in microarray technology allow
researchers to accurately and precisely measure gene
expression patterns in lymphomas which provides the
opportunity to revolutionize the way these tumors are
grouped and treated. In other words, studying gene
expression proﬁles in lymphomas may provide the oppor-
tunity to identify pathways on which the tumor depends
and to target the pathways for the development of
new drugs. Indeed, gene-expression proﬁling studies
have distinguished three molecular subtypes of DLBCL:
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germinal-center B-cell-like (GCB) DLBCL, activated B-
cell-like (ABC) DLBCL, and primary mediastinal B-cell
lymphoma (PMBL) [2,5-8].
The ﬁrst attempt at examining gene expression proﬁl-
ing to identify distinct B-cell malignancies was made by
Alizadeh et al. [9]. A hierarchical clustering algorithm
[10] was used to group genes on the basis of similarity
of their expression over all subjects. Subjects were also
grouped based on the similarities in gene expression using
the same clustering method. Two distinct subgroups of
DLBCL were found based on the gene expression analysis:
GCB DLBCL and ABC DLBCL. Alizadeh et al. [9] discov-
ered that almost all genes that deﬁned GCB DLBCL were
highly expressed in normal germinal center B cells and, by
contrast, most genes that deﬁned ABC DLBCL were not
expressed in normal germinal center B cells. In addition,
there was a substantial and signiﬁcant diﬀerence in the
average ﬁve-year survival rate between patients with GCB
DLBCL and ABC DLBCL.
Inspired by the work of Alizadeh [9], Rosenwald et al.
[5] found that most of the genes with expression patterns
that correlated with survival of the DLBCL subgroups fell
within four gene-expression signatures. A gene-expression
signature is a group of genes expressed in a speciﬁc cell
lineage or stage of diﬀerentiation or during a particular
biologic response and hence genes within the same gene-
expression signature are probably associated with similar
biologic aspects of tumor [5]. The authors in [5] then devel-
oped a molecular predictor consisting of 17 genes for
the likelihood of survival after chemotherapy according
to gene expression proﬁles of lymphomas. Shipp et al. [4]
adopted the weighted-voting algorithm [11] to develop an
outcome predictor with 13 genes and were able to classify
two categories of DLBCL patients with very diﬀerent ﬁve-
year overall survival rates. Note that there is no overlap
among the genes in the models derived in [4] and [5].
Wright et al. [8] formulated a DLBCL subgroup pre-
dictor based on Bayes’ rule, applied this method to the
DLBCL gene expression data in [5], and constructed a
27-gene DLBCL subgroup predictor. Next, a new predic-
tor including 14 genes among the previous predictor was
constructed and applied to another set of gene expression
data fromDLBCLs [4]. Wright et al. [8] also demonstrated
that the proposed algorithm can deﬁne cancer subgroups
based on gene expression diﬀerences regardless of the
DNA microarray platforms and could be used clinically
to provide diagnostic information as the resulting survival
rates were signiﬁcantly diﬀerent for the identiﬁed GCB
and ABC DLBCL subgroups.
A panel of 36 genes whose expression predicts survival
in DLBCL was identiﬁed by Lossos et al. [1] through lit-
erature review. They [1] selected 6 out of the 36 genes by
ranking them on the basis of their predictive power for
DLBCL survival obtained by univariate analysis. A 6-gene
multivariate Cox proportional-hazards regression model
for prediction of survival in DLBCL was constructed and
applied to the data from [4] and [5]. Lossos et al. [1] con-
cluded that the measurement of the expression of the six
genes was suﬃcient to predict overall survival in DLBCL
after stratifying patients into diﬀerent risk groups based
on their IPI score.
More recently, Blenk et al. [12] analyzed an enlarged
data set (original data were generated by [5]) to conﬁrm
that there are clear expression diﬀerences between ABC
andGCBDLBCL. To detect diﬀerentially expressed genes,
they [12] used limma in [13] and further determined
50 best separating genes for class discovery. An optimal
classiﬁer with only 18 genes for distinguishing DLBCL
subgroups was conducted. In addition, an optimal molec-
ular survival predictor with only six genes was obtained.
However, there was no overlap among the genes used in
the classiﬁer and the survival predictor established in [12].
Models introduced in [1,4,5,8,9,12] can be used to dis-
tinguish the subgroups in DLBCL and identify rational
targets for research into treatment intervention. More-
over, the predictor identiﬁed by each study involved only
a small number of genes and thus the needed DNA
microarrays may be easily developed for clinical predic-
tion. Nonetheless, genes seldom overlap in these models.
Blenk et al. [12] showed that 6 of the 18 genes used in the
optimal classiﬁer were found again after analyzing another
data set from [4]. However, none of these genes were
identiﬁed in a subsequent investigation of survival [12].
Due to technical diﬀerences, the composition of the
microarrays used, and the diﬀerent algorithms used for
constructing predictive models, it remains unclear which
method and which model best captures the molecular and
clinical heterogeneity of diﬀuse large-B-cell lymphoma.
Therefore, the goal in this research was to give an example
of how bivariate data can be used for clinical research.
Methods
Let Xaij and Xhil denote gene expression measurements
from the ith orthologous gene pair [14] for the jth ani-
mal and the lth human. The following independent linear
models describe the association between gene expression
and treatment (cancer type):
Xaij = β0ai + β1aiTaj + eaij , (1)
Xhil = β0hi + β1hiThl + ehil , (2)
where Taj and Thl are {0, 1} treatment indicators, and
eaij and ehil are independent N(0, σ 2a ) and N(0, σ 2h ) ran-
dom variables. The σ 2a and σ 2h are variances for eaij and
ehil , respectively. A given gene can be classiﬁed as non-
diﬀerentially expressed (NDE, showing no signs of treat-
ment eﬀects), positively diﬀerentially expressed (pDE,
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showing positive treatment eﬀects), or negatively dif-
ferentially expressed (nDE, showing negative treatment
eﬀects). Furthermore, we assume dependency between
diﬀerentially expressed orthologs. Therefore, for a human
and animal gene pair, there are nine possibilities for cate-
gorizing this pair of genes, illustrated in Table 1.
The following two-species nine-component bivariate
normal mixture model in [15,16] is proposed to simul-
taneously model the vectors of the estimated treatment
eﬀects (βˆ1ai , βˆ1hi)T obtained from Equations 1 and 2:(
βˆ1ai
βˆ1hi
)
∼ π0N
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0
0
)
,
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) )
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where πk , k = 0, . . . , 8 denote the mixing weights (the
probability that an observation belongs to the kth compo-
nent). Note that
∑8
k=0 πk = 1 and πk ≥ 0 . (μak ,μhk)T
and (σ 2ak , σ 2hk)T are the vectors of themeans and variances,
respectively, for each species in each mixture component.
ρk denotes the correlation between orthologs under the
kth category. To accommodate the possible patterns of
Table 1 Possible categories of (β1ai ,β1hi)T
Category (β1ai ,β1hi ) (μβ1ai ,μβ1hi ) Corr(β1ai ,β1hi )
0 (NDE,NDE) (0, 0) 0
1 (pDE,pDE) (+,+) ρ1
2 (nDE,nDE) (−,−) ρ2
3 (pDE,nDE) (+,−) ρ3
4 (nDE,pDE) (−,+) ρ4
5 (NDE,pDE) (0,+) 0
6 (NDE,nDE) (0,−) 0
7 (pDE,NDE) (+, 0) 0
8 (nDE,NDE) (−, 0) 0
the gene expression for animal and human due to treat-
ment intervention (diﬀerent cancer types), the following
constraints are imposed: μa1 ≥ 0, μh1 ≥ 0, μa2 ≤ 0,
μh2 ≤ 0, μa3 ≥ 0, μh3 ≤ 0, μa4 ≤ 0, μh4 ≥ 0, μh5 ≥ 0,
μh6 ≤ 0, μa7 ≥ 0, and μa8 ≤ 0; ρ0 = 0, ρ5 = 0, ρ6 = 0,
ρ7 = 0, and ρ8 = 0.
Gene membership is determined according to the
maximum posterior probability that an observation
(βˆ1ai , βˆ1hi)T comes from the kth component of the
mixture.
A parametric bootstrap method in [17,18] to estimate
the standard errors for the estimated parameters is pro-
vided. Bootstrapping is the practice of estimating proper-
ties of an estimator by measuring those properties when
sampling from an approximating distribution. The basis
of the bootstrap methodology is simple. In the paramet-
ric bootstrap setting, consider F to be a member of some
prescribed parametric family and obtain F̂n by estimat-
ing the family parameters, in this case, (πk ,μak ,μhk ,k)T ,
k = 0, . . . , 8 , from the data. In each iteration, by
generating an iid random sequence, called a ‘resample’
from the distribution F̂n, new estimates of the param-
eters are obtained and the sampling properties (such
as the mean, standard deviation, bias, and shape) can
be evaluated.
The procedure of the parametric bootstrap resampling
method to obtain the estimated standard errors of the esti-
mated parameters for the nine-component mixture model
is described as follows:
1. F̂n is formed by substituting the estimates of
(μak ,μhk)T and k into the 9-component mixture
model (3).
2. The numbers of genes in category 0 through category
8 (n0, n1, . . . , n8) are drawn from a multinomial
distribution with parameters n and p . n is the
number of trials for each multinomial random
variable. In this study, it is equal to the number of
orthologs in two-species data. p is the vector of event
probabilities for each trial. In this study, p is the
vector of the mixing weights estimated from the data.
The new mixing weights are then calculated for the
bootstrap resampling and plugged into the
nine-component mixture model (Equation 3) to form
F̂n .
3. Bootstrap samples (βˆ∗1ai , βˆ
∗
1hi)
T of size n are drawn
from F̂n formed above.
4. For each bootstrap resampling, obtain the
numerically approximated maximum likelihood
estimates for the parameters in the nine-component
mixture using the expectation-maximization (EM)
algorithm.
5. Repeat steps 1 to 4 B times independently. B is the
number of bootstrap replications. Calculate the
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empirical standard deviation of a series of bootstrap
replications of θˆ accordingly. θˆ is the estimator of θ ,
the parameter of interest. Since the standard error of
the mean (s/√n, sample standard deviation divided
by the squared root of the size of the sample) is the
estimate of the true standard deviation of the sample
mean (σ/
√n, standard deviation for the population
divided by the squared root of the size of the sample),
essentially, the standard deviation of the bootstrap
estimator obtained here is an estimation of the
standard error of the mean for the parameter of
interest. The bootstrap standard error ŜEB of θˆ is
calculated as follows:
ŜE(θˆ)B =
√√√√ 1
B − 1
B∑
b=1
(θˆ∗b − ¯ˆθ∗)2,
where θˆ∗b is the estimator of θ calculated from the bth
bootstrap resample (b = 1, . . . ,B) , ¯ˆθ∗ =∑Bb=1 θˆ∗b /B;
B is the total number of resamples (each of size n)
collected from the empirical estimate of F.
Data sources
In order to improve treatments for non-Hodgkin lym-
phoma in human and canine patients, researchers from
North Carolina State University’s College of Veterinary
Medicine and the University of North Carolina at Chapel
Hill Lineberger Comprehensive Cancer Center conducted
research to study tissue samples from human and canine
non-Hodgkin lymphoma patients, with the hope of cre-
ating a genomic proﬁle of non-Hodgkin lymphoma that
would give oncologists and veterinarians greater insight
into the disease’s biology and obtain the information
that could lead to a clinical beneﬁt for both species.
The study protocol was approved by the Institutional
Animal Care and Use Committee of North Carolina
State University.
The team recruited dogs diagnosed with lymphoma
to collect tissue samples for study. The dog data were
measured at the probe set level on Aﬀymetrix Canine
Genome 2.0 array (Canine 2, Aﬀymetrix Inc., Santa Clara,
CA, USA), with a total number of probe sets equal to
43,035. Forty-eight dogs with one of the following diag-
nostic results were recruited: B-cell lymphoma (27 dogs),
T-cell lymphoma (10 dogs), B-cell acute lymphoblastic
leukemia (1 dog), T-cell acute lymphoblastic leukemia (4
dogs), and normal (6 dogs). Among the 27 dogs with
B-cell lymphoma, 14 of them were diagnosed histopatho-
logically with DLBCL. The 14 DLBCL patients could
be further divided into two subgroups: 5 ABC DLBCL
patients and 9 GCB DLBCL patients. For the purpose
of this research, only data for the 14 dogs with DLB-
CLs were used. The dog microarray gene expression
data were LOESS normalized by JMP Genomics 4.0
(Cary, NC, USA).
Corresponding data for human patients with lymphoma
were extracted from the Gene Expression Omnibus
(GEO) database [19]. Data for 460 lymphoma patients
were retrieved from two series with GEO accession num-
ber: GSE10846 [7] and GSE11318 [6]. The human data
were measured at the probe set level on Aﬀymetrix
Human Genome U133 2.0 array (HG-U133 Plus 2), with
a total number of probe sets equal to 54,675. The human
microarray gene expression data were also LOESS nor-
malized by JMP Genomics 4.0. Based on the gene expres-
sion, two distinct subgroups were identiﬁed after principle
component analysis. This implied that there may be a
strong batch eﬀect among the samples. Hence, only sam-
ples from one of these two subgroups were included in
the data analysis. This resulted in 219 human subjects
consisting of 31 PMBL, 78 ABC DLBCLs, 80 GCB DLB-
CLs, and 29 unclassiﬁed DLBCLs (distinguishing between
subgroups of DLBCL is through gene-expression proﬁling
[6,7]). To make the animal and human data comparable,
only data for ABC and GCB DLBCLs with correspond-
ing survival information were used. This resulted in a ﬁnal
dataset with 77 ABCDLBCL patients and 79 GCBDLBCL
patients.
After averaging probe sets across a gene to obtain a
gene-level transcript value, the orthologous information
from HomoloGene release 64 at website ftp://ftp.ncbi.nih.
gov/pub/HomoloGene/build64/ was applied to acquire
the mappings between dog and human. This led to a total
of 6,566 pairs of dog and human orthologs.
Data analysis
We recall that the objective of the data analysis was to
identify rational targets (genes) for treatment interven-
tion simultaneously for both dog and human lymphoma
patients with the hope of giving researchers greater insight
into the disease’s biology. Furthermore, it was also of inter-
est to verify if the targeted genes can serve as a good
predictor to clinically distinguish subgroups of DLBCL
in humans. Because the samples in humans that were
used to estimate the distribution of the bivariate mixture
model were also used to build the classiﬁcation func-
tion, there was a possibility of over-ﬁtting, resulting in a
model that would indicate an over-optimistic separation
between the subgroups than would be found in inde-
pendent data. To avoid the biased classiﬁcation result, a
leave-one-out-cross-validation (LOOCV) procedure [20]
was introduced as the following steps:
1. Use all 14 observations for dogs and obtain the
estimated coeﬃcients of cancer type eﬀect on gene
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expression βˆ1ai , i = 1, . . . , 6, 566 . Omit one
observation from the 156 human observations and
obtain the estimated coeﬃcients of cancer type eﬀect
βˆ1hi .
2. Use all (βˆ1ai , βˆ1hi)T to construct the nine-component
bivariate normal mixture model. Identify gene
membership accordingly.
3. Use genes classiﬁed into categories (1, 2, 3, and 4)
(diﬀerentially expressed in both species) to develop a
classiﬁcation rule based on the remaining 155 human
observations. Develop another classiﬁcation rule
based on genes classiﬁed into categories (1, 2, 3, 4, 5,
and 6) (diﬀerentially expressed in human).
4. For the purpose of comparison, identify diﬀerentially
expressed human genes by performing a single
species analysis for human only. Choose genes based
on the p values of the t statistics after adjusting for
multiple comparison by controlling the false
discovery rate (FDR) [21] at levels 0.01 and 0.00001.
5. Classify the holdout human observation using the
classiﬁcation rules constructed in steps 3 and 4.
6. Repeat steps 1, 2, 3, 4 and 5 until every one of the
human observations is classiﬁed.
The classiﬁcation rule was established through the M-
dimensional centroid obtained from the k-means [22]
clustering process applied to the training set. M was the
number of genes retained for performing cancer type clas-
siﬁcation. k was equal to 2 as there were two types of
cancer. SAS PROC FASTCLUS [23] was used to carry out
the k-means clustering.
Since k-means does the clustering, and not the classi-
ﬁcation, the class of each cluster has to be determined
for the classiﬁcation rule before it can be used to classify
future observations. Table 2 demonstrates the results of
the k-means clustering.
Clusters were designated so that the minimum misclas-
siﬁcation rate was achieved. Therefore,
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
if n12 + n21 < n22 + n11
⇒ cluster 1 = “ABC DLBCL” and cluster 2 = “GCB DLBCL”,
if n12 + n21 > n22 + n11
⇒ cluster 1 = “GCB DLBCL” and cluster 2 = “ABC DLBCL”,
if n12 + n21 = n11 + n22
⇒ randomly assign cluster labels.
Table 2 The k -means clustering results
Cluster 1 Cluster 2
ABC DLBCL n11 n12
GCB DLBCL n21 n22
The classiﬁcation rule established at the lth LOOCV
procedure was then⎧⎪⎪⎨
⎪⎪⎩
if
∑Ml
m=1(xhml − μcentroidl,1m )2 <
∑Ml
m=1(xhml − μcentroidl,2m )2
⇒ classify the lth human subject into cluster 1,
else ⇒ classify the lth human subject into cluster 2.
Ml was the total number of genes retained at the lth
LOOCV procedure for cancer type classiﬁcation. l =
1, . . . , 156 , as there were 156 human DLBCL patients.
xhml was the mth gene expression for the lth hold-out
human subject. For the lth LOOCV procedure, μcentroidl,1m
andμcentroidl,2m were themth centroidmeans (m = 1, . . . ,Ml)
calculated from the k-means (k = 2) algorithm for cluster
1 and cluster 2, respectively.
Results
Parameter estimation
The maximum likelihood estimates of the parameters
in the nine-component bivariate normal mixture model
computed using the EM algorithm [24] are given in
Table 3. The estimated mixture weight for category 0
was πˆ0 = 0.823 indicating approximately 5,404 (6, 566 ×
0.823) pairs of uninteresting dog and human orthologs.
(μa,μh)T denotes the mean vector of each mixture com-
ponent. Most of the estimated mean vectors were slightly
larger in categories 1 through 4 than those in categories 5
through 8. It appeared that themagnitude of the estimated
diﬀerence of expression in genes related to lymphoma
in both species tended to be larger than in genes where
diﬀerential expression was exhibited in only one species.
Gene selection and cancer type classiﬁcation
For the 156 LOOCV instances, the proposed mixture
model determined 21 (14 genes appearing in the intersec-
tion of all hold-outs) human genes in categories (1, 2, 3,
and 4) and 279 (185 genes appearing in the intersection of
all hold-outs) human genes in categories (1, 2, 3, 4, 5, and
6). While analyzing the human data alone and controlling
the FDR at levels 0.01 and 0.00001, 935 (706 genes appear-
ing in the intersection of all hold-outs) and 190 (139 genes
appearing in the intersection of all hold-outs) genes were
identiﬁed as diﬀerentially expressed, respectively. Figure 1
shows the scatter plots of (βˆ1a, βˆ1h)T for all orthologs and
the 21 pairs of orthologs in categories (1, 2, 3, and 4); i.e.,
the genes in this group showed evidence of distinguish-
ing the two types of cancer for both species. Clearly, most
of the pairs scattered around the (0, 0) origin, indicating
that these genes (for both species) did not have poten-
tial for serving as markers that could distinguish the two
subgroups of DLBCL.
After identifying human genes that showed signs of dis-
criminating between ABC DLBCL and GCB DLBCL and
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Table 3 Summary of parameter estimates for the bivariate mixture model averaged over the 156 LOOCV outcomes
Parameter
Category πk μak μhk σ 2ak ρkσakσhk σ
2
hk
0 0.823(0.077) NE NE 0.013(0.001) NE 0.012(0.001)
1 0.001(0.005) 0.341(0.081) 0.022(0.130) 0.004(0.010) 0.001(0.017) 0.022(0.060)
2 0.001(0.001) -0.602(0.243) -0.831(0.193) 0.199(0.082) -0.128(0.048) 0.089(0.036)
3 0.001(0.004) 0.495(0.195) -0.564(0.244) 0.042(0.078) -0.042(0.041) 0.119(0.074)
4 0.000(0.003) -1.131(0.422) 0.758(0.305) 0.000(0.028) 0.000(0.015) 0.000(0.050)
5 0.020(0.008) NE 0.492(0.121) 0.020(0.021) NE 0.058(0.049)
6 0.011(0.004) NE -0.517(0.136) 0.034(0.093) NE 0.040(0.044)
7 0.130(0.077) 0.331(0.038) NE 0.018(0.009) NE 0.025(0.001)
8 0.012(0.008) -0.478(0.339) NE 0.011(0.051) NE 0.042(0.054)
Numbers in parentheses are the bootstrap standard errors; B = 5, 000 (the number of bootstrap replications); NE not estimated.
based either on two-species analysis (the nine-component
bivariate mixture model) or on single-species (human
only) analysis, the next step in the LOOCV procedure
was to classify the hold-out human subject according to a
classiﬁcation rule established using the same set of genes.
Table 4 summarizes the classiﬁcation results over the 156
LOOCV instances under the four diﬀerent gene selection
criteria. It was interesting to see that using human genes
from categories (1, 2, 3, and 4), categories (1, 2, 3, 4,
5, and 6) (two-species analysis), and the genes selected
by controlling FDR at 0.00001 (single-species analysis)
gave a very similar number of misclassiﬁcations, 17, 16,
and 19, respectively. Nonetheless, choosing FDR = 0.01,
the gene list was largely expanded. The enlarged gene
(a) (b) (c)
(d) (e)
Figure 1 Scatter plots of (βˆ1a, βˆ1h)T . (a) all orthologs, (b) orthologs diﬀerentially expressed in both species (categories (1, 2, 3, and 4)), (c)
orthologs for which the corresponding human genes are diﬀerentially expressed (categories (1, 2, 3, 4, 5, and 6)), (d) orthologs identiﬁed by analyzing
the human data alone and controlling FDR at 0.00001, and (e) orthologs identiﬁed by analyzing the human data alone and controlling FDR at 0.01.
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Table 4 Misclassiﬁcation tables using diﬀerent criteria
Categories (1, 2, 3, and 4) Categories (1, 2, 3, 4, 5, and 6) FDR = 0.00001 FDR = 0.01
Model prediction/subgroup ABC GCB ABC GCB ABC GCB ABC GCB
ABC DLBCL 72 5 64 13 58 19 0 77
GCB DLBCL 12 67 3 76 0 79 2 77
list resulted in a very poor classiﬁcation result: 79 sub-
jects were misclassiﬁed, among whom the entire group
of ABC DLBCLs were misclassiﬁed as GCB DLBCLs.
Misclassiﬁcation rates were 0.109, 0.103, 0.122, and 0.506,
accordingly. It was reasonable to conclude that the clas-
siﬁcation results based on two-species (dog and human)
data, in general, may outperform those based on only
single-species (human) data.
Prognostic DLBCL sub-categories deﬁned by gene
expression proﬁles
Does the taxonomy of DLBCL derived from gene expres-
sion patterns deﬁne clinically distinct subgroups of
patients? To conﬁrm that these two DLBCL subgroups
deﬁned by gene expression (the 21 genes in categories
(1, 2, 3, and 4)) were both biologically and clinically dis-
tinct so that the mixture model approach could form the
basis of a robust diagnostic test that may prove useful in
assessing the results of therapeutic trials in DLBCL, over-
all survival and subgroup survival based on two types of
gene-expression proﬁling, in [6] and [7] and the proposed
mixture model approach, were plotted.
Figure 2 shows the nonparametric Kaplan-Meier sur-
vival probability estimates [25] for patients with DLBCL
under two situations, unstratiﬁed and stratiﬁed, by gene-
expression proﬁling. Treating the DLBCL patients regard-
less of the biological diﬀerence between the subgroups
gave a 5-year survival rate of 45%. The 5-year survival
rates after stratifying the patients according to the gene-
expression proﬁling performed in [6] and [7] were 31%
for ABC DLBCL and 59% for GCB DLBCL as compared
with the rates of 29% for ABC DLBCL and 64% for GCB
DLBCL if patients were stratiﬁed by the gene-expression
proﬁling results based on the proposed nine-component
mixture model. Under both types of stratiﬁcation, ABC
and GCBDLBCL were associated with statistically signiﬁ-
cant diﬀerences in overall survival (p<0.0001). A log-rank
test [26] was used to test the hypothesis of equal survival
functions. The molecular dissection of DLBCL by gene-
expression proﬁling using the proposed nine-component
mixture model apparently identiﬁed diﬀerent features of
these patients that inﬂuence their survival.
As determined by gene-expression proﬁling performed
in [6] and [7], among the 156 patients, there were 77 ABC
DLBCLs and 79 GCB DLBCLs. Conversely, the stratiﬁ-
cation stated by the gene-expression proﬁling using the
proposed nine-component mixture model gave a result
of 84 ABC DLBCLs and 72 GCB DLBCLs. More specif-
ically, ﬁve of the ABC DLBCLs had been classiﬁed as
GCB DLBCLs, and 12 of the GCB DLBCLs had been
categorized as ABC DLBCLs. However, the diﬀerence
between themedian survival time (years) of the subgroups
stratiﬁed by gene-expression proﬁling performed in [6]
and [7] was smaller than that of the subgroups stratiﬁed
by gene expression proﬁling using the proposed nine-
component mixture model (8.76 vs. 9.31). This may imply
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Figure 2 Kaplan-Meier survival probability estimates for the dog and human lymphoma study. (a) No stratiﬁcation, (b) stratiﬁcation based
on the results of gene-expression proﬁling performed in [6] and [7], and (c) stratiﬁcation based on the gene-expression proﬁling resulted from the
proposed nine-component mixture model. Numbers in parentheses are medians.
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that the stratiﬁcation based on the gene expression pro-
ﬁling using the proposed nine-component mixture model
provided better insight for the clinical diﬀerence between
ABC and GCB DLBCL. These results suggested that the
microarray-based outcome predictor not only reﬂected
the clinical diﬀerence between the twoDLBCL subgroups,
but also provided a possible strategy of investigation for
further individualization of patient treatment.
Justiﬁcation of the 21 selected human genes
To validate the relevance between speciﬁc genes and phe-
notypes, a careful search of the literature was undertaken
using Entrez Gene [27]. Some of these 21 genes (the genes
in Table 5 with Entrez ID highlighted in italics) were iden-
tiﬁed by this search as potentially associated with the
development of DLBCL. A brief summary of the relation-
ship between these candidate genes and the development
of DLBCL is given as follows:
1. CD39 [Entrez Gene:953] is a B lymphocyte activation
marker and has powerful functions in the immune
system [28].
2. The expression pattern of JAW1 [Entrez Gene:4033],
a lymphoid-restricted protein, suggested that this
protein may have a role in the developmentally
regulated traﬃcking of the antigen receptors in B
cells and may inﬂuence lymphoid development [29].
Tedoldi et al. [30] pointed out that high levels of Jaw1
mRNA were found in germinal center B-cells and in
diﬀuse large B-cell lymphomas of germinal center
subtype.
3. The importance of LMO2 [Entrez Gene:4005],
though its function in germinal center cells is
unknown, as a candidate marker involved in the
development of DLBCL has been discussed in several
papers. Natkunam et al. [31] studied LMO2 at the
protein level and conﬁrmed that LMO2 is expressed
speciﬁcally in germinal center B cells, which is fully in
keeping with gene-expression proﬁling studies that
showed high levels of LMO2 mRNA in germinal
center B cells. They in [31] also observed that among
DLBCLs, LMO2 tended to be expressed in cases
assigned by phenotyping to the GCB categories and
can therefore be added to the panel of markers that
pathologists may use to subcategorize lymphomas.
Morton et al. [32] claimed that LMO2 is one of the
candidate genes involved in lymphocyte development
and is highly expressed in germinal center
lymphocytes. Durnick et al. [33] studied the
relationship between LMO2 expression and
t(14;18)/IGH-BCL2, a speciﬁc marker of lymphomas
of germinal center origin and has been speciﬁcally
associated with the GCB subgroup of DLBCL as
determined by gene expression proﬁling but not in
the ABC cases. There was a statistically signiﬁcant
association between IGH-BCL2 fusion and LMO2
protein expression and hence LMO2 was suggested
as a potential marker for the GCB phenotype. A
similar conclusion has also been reached by [1].
4. Germinal center B lymphocytes prominently express
at least two regulators of G-protein signaling (RGS)
proteins, RGS1 and RGS13 [Entrez Gene:6003]. RGS
is a family of proteins acting to limit and modulate
heterotrimeric G-protein signaling. Han et al. [34]
discovered that RGS1 and RGS13 act together to
regulate chemokine receptor signaling in human
germinal center B lymphocytes. The results provide
some insight toward ﬁnding methods to reduce or
eliminate an organism’s negative reaction to a
treatment stimulus.
5. The importance of the transcription factor FOXP1
[Entrez Gene:27086] as marker for the activated
B-cell-like signature has been well-established [5,9].
Banham et al. [35] investigated the prognostic
importance of FOXP1 protein expression in DLBCL
and found that the overall empirical survival curves
for the two subgroups based on the expression of
FOXP1 are signiﬁcantly diﬀerent. Goatly et al. [36]
made an attempt to discover the underlying
molecular mechanism of FOXP1 expression in
lymphoma development by investigating the FOXP1
translocation, copy number change, and protein
expression in mucosa-associated lymphoid tissue
lymphoma and DLBCL. Korac and Dominis [37]
explored the association between FOXP1, BCL2, and
BCL6 gene expression in diﬀuse large B-cell
lymphoma tumor cells. FOXP1 protein was detected
in 28 patients; genetic abnormalities involving the
FOXP1 locus were found in 19 patients, and both
were present in 13 patients, among the samples of
lymph nodes from 53 patients with newly diagnosed
DLBCL. FOXP1 genetic abnormalities have been
found to be associated with both BCL2 and BCL6
expression. Though it has been discovered that BCL2
and BCL6 proteins have an impact on diﬀuse large B-
cell lymphoma development and outcome, they may
not be good prognostic markers. FOXP1 has played a
role in the development of DLBCL. The identiﬁed
association among FOXP1, BCL2, and BCL6 indicates
the possibilities of uncovering the development
process in diﬀuse large B-cell lymphoma tumor cells.
In addition, Nyman et al. [38] used FOXP1 and
MUM1/IRF4 as activated B-cell-like markers to
distinguish patients between the activated B-cell-like
and other diﬀuse large B-cell lymphoma subtypes.
Most recently, six common prognostic biomarkers,
including FOXP1, were used to conclusively decide
the cut-oﬀ values calculated by receiver operating
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Table 5 Summary of the gene-speciﬁc information (retrieved from Entrez Gene, an NCBI’s database for gene-speciﬁc
information)
Entrez Gene ID Category Dog ortholog Frequencya Symbol Oﬃcial full name
953 1 486810 156 CD39; ATPDase; Ectonucleoside triphosphate
FLJ40921; FLJ40959; diphosphohydrolase 1
NTPDase-1;
DKFZp686D194;
DKFZp686I093; ENTPD1
1278 2 403824 156 OI4; COL1A2 Collagen, type I, alpha 2
2530 1 448804 156 MGC26465; FUT8 Fucosyltransferase 8 (alpha (1,6) fucosyltrans-
ferase)
4005 2 609006 156 TTG2; RBTN2; RHOM2; LIM domain only 2 (rhombotin-like 1)
RBTNL1; LMO2
4033 3 486631 156 JAW1; LRMP Lymphoid-restricted membrane protein
5919 2 475532 156 TIG2; HP10433; RARRES2 Retinoic acid receptor responder (tazarotene
induced) 2
6003 3 612789 124 MGC17173; RGS13 Regulator of G-protein signaling 13
6856 3 475889 154 SYPL; H-SP1; SYPL1 Synaptophysin-like 1
6925 1 403949 156 E2-2; ITF2; PTHS; SEF2; Transcription factor 4
SEF2-1; SEF2-1A; SEF2-1B;
bHLHb19; MGC149723;
MGC149724; TCF4
7037 1 403703 11 TFR; CD71; TFR1; TRFR; Transferrin receptor (p90, CD71)
TFRC
9435 1 485701 156 C6ST; GST2; GST-2; Gn6ST-
1; CHST2
Carbohydrate (N-acetylglucosamine-6-O)
sulfotransferase 2
9760 2 486964 156 TOX1; KIAA0808; TOX Thymocyte selection-associated high mobil-
ity group box
10447 3 612336 154 ILEI; GS3786; FAM3C Family with sequence similarity 3, member C
23075 3 485385 4 HSPC321; SWAP-70; SWAP switching B-cell complex 70kDa
FLJ39540; KIAA0640; subunit
SWAP70
25816 1 481428 156 GG2-1; SCCS2; SCC-S2; Tumor necrosis factor, alpha-induced
MDC-3.13; TNFAIP8 protein 8
27086 1 484692 156 QRF1; 12CC4; hFKH1B; Forkhead box P1
HSPC215; FLJ23741;
MGC12942; MGC88572;
MGC99551; FOXP1
56941 2 484628 156 DC12; MGC111075; Chromosome 3 open reading frame 37
C3orf37
81552 1 608562 145 ECOP; GASP; FLJ20532; Vesicular, overexpressed in cancer,
DKFZp564K0822; VOPP1 prosurvival protein 1
81641 1 479002 116 Apm; Apn; KZP; AP-M; AP-
N; Lap1; rAPN; Anpep
Alanyl (membrane) aminopeptidase
121355 4 477590 156 FAM112B; FLJ32942; Gametocyte speciﬁc factor 1
GTSF1
219972 1 475960 156 MPG1; MGC132657; Macrophage expressed 1
MGC138435; MPEG1
For the 21 human genes in categories (1, 2, 3, and 4) determined by the bivariate mixture model.
Genes in italicswere identiﬁed by this search as potentially associated with the development of DLBCL.
anumber of times the corresponding gene was found in the classiﬁcation gene set for the 156 LOOCV instances.
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curves to predict survival for DLBCL patients [39].
All these results suggested that FOXP1 expression
may be important in DLBCL pathogenesis.
Among the 21 selected genes, ﬁve (from categories 1,
2, and 3) have been carefully examined to explore their
association with the development of lymphoma. From
the mixture model assumption, genes in the same cate-
gory should react to the stimulus (drug treatment, cancer
type, etc.) in a similar manner. Hence, the implications of
these 21 genes (some of them may not have been stud-
ied scrupulously) in lymphoma may provide timely and
important insight on guiding future investigations of their
roles in both B-cell biology and lymphoma development.
Conclusions
Since the development of high throughput gene expres-
sion technology, the important and diﬃcult task of
searching for genes that exhibit diﬀerences across species
(cancer types or treatment groups in drug trials) has been
the focus of much research. Simultaneously analyzing
gene expression across two species takes into account the
biological similarity between diﬀerent organisms while
identifying genes that could be potential prognostic mark-
ers and increase the power to detect diﬀerences. Identiﬁ-
cation of the relevant genes and a better understanding of
the associated molecular pathways may open new possi-
bilities in cancer diagnosis and treatment. Furthermore, it
may become a practical assay for newly diagnosed patients
to optimize their clinical management.
In this case study, the application of the proposed
nine-component mixture model successfully reduced the
quantities of variables (genes) needed to be investigated
for the study of two types of DLBCL in humans. The
dimension of variables decreased from 6,566 to 21, a clus-
ter of genes that were identiﬁed as being diﬀerentially
expressed in both species. On the other hand, an anal-
ysis of data from one species that selected genes using
a speciﬁed FDR led to a much longer list of diﬀeren-
tially expressed human genes (935 genes with FDR = 0.01
and 190 with FDR = 0.00001). Furthermore, the misclas-
siﬁcation rate for human cancer type classiﬁcation using
clustering with gene expression from these 21 genes iden-
tiﬁed by the bivariate mixture model was remarkably low.
The survivorship of the patients stratiﬁed according to
this clustering was very diﬀerent across the two types of
cancer, indicating that the stratiﬁcation based on gene-
expression proﬁling using the proposed nine-component
mixture model provided better insight for the clinical
diﬀerences between the two types of cancer.
While validating the relevance of the identiﬁed human
genes through NCBI’s database, literature, if any, for the
corresponding dog orthologs were also searched. Far less
research about DLBCL has been conducted for canines.
As the model assumption is based on the biological
mechanism behind humans and animals, the promising
DLBCL classiﬁcation results based on the human genes
may be extended to dogs. Furthermore, currently, direct
experiments on humans are not practical. This research
provides the possibility for scientists to conduct observa-
tional or experimental research on modeling organisms as
the ﬁrst step to understand phenotypes, and then extend
the ﬁndings to humans for further investigation.
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